New York, NY -- February 10, 2020 -- via NextBigTicker.com 


Puration, Inc. (USOTC:PURA) just experienced a major technical breakthrough with an MACD cross and is pushing on a second breakthrough for the day with as the PPS approaches the $0.039 50 Day Moving Average.  PURA hit $0.09 last September after trading in the $0.04 range days prior.  Last March, PURA hit $0.15 after trading in the $0.06 range days prior.  PURA looks well staged to see another one of its historic periodic PPS surges triggered by news.  Today the company announced closing a $5 million investment to fund CBD infused beverage, edible and topical acquisitions.  The news today reported that the first formal acquisition proposal will be going out later this week.

Analyst Speculative Buy and $0.35 PPS Target
 

PURA on Wednesday last week announced a next iteration of an ongoing CBD consumer survey conducted by Goldman Research on behalf of PURA to gauge and refine the company’s ongoing approach to the CBD consumer market. 

The Goldman CBD consumer survey included a PURA speculative BUY recommendation and at $0.35 target PPS.  PURA closed yesterday at $0.29.  Realizing the target PPS could deliver a 1000% ROI. 

The full CBD consumer survey update can be viewed at GOLDMAN CBD SURVEY.

Other trending stock opportunities today include Northwest Biotherapeutics (NWBO), Anavex Life Sciences (AVXL) and CAVU Resources (CAVR)


Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: 
www.nextbigticker.com

Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Anavex Life Sciences Charts.